<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04352855</url>
  </required_header>
  <id_info>
    <org_study_id>SE58/2020</org_study_id>
    <nct_id>NCT04352855</nct_id>
  </id_info>
  <brief_title>Ceftolozane-tazobactam for the Treatment of Respiratory Infections Due to Extensively Drug-resistant Pseudomonas Aeruginosa Among Critically Ill Patients: a Retrospective Study.</brief_title>
  <official_title>Ceftolozane-tazobactam for the Treatment of Respiratory Infections Due to Extensively Drug-resistant Pseudomonas Aeruginosa Among Critically Ill Patients: a Retrospective Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Semmelweis University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Semmelweis University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to report our experience with ceftolozane-tazobactam and to evaluate
      its safety and efficacy in the treatment of ICU dependent nosocomial respiratory tract
      infections due to extensively drug resistant Pseudomonas aeruginosa. Different dosing regimes
      of ceftalozane-tazobactam is evaluated and compared to the standard therapy of Colomycin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ceftolozane-tazobactam (C/T) is a novel type of beta-lactam/beta-lactamase inhibitor
      antibiotics targeting nosocomial infections caused by Gram-negative bacteria. In recent
      years, ceftolozane-tazobactam was prescribed for treating complicated urinary tract
      infections (cUTI) and complicated intraabdominal infections (cIAI). Following the results of
      ASPECT-NP trial in 2019, it was approved as a therapeutic option in nosocomial pneumonia
      including hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP).

      The drug shows an excellent activity against ESBL-producing Enterobacterales and
      multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Pseudomonas
      aeruginosa. The latter is widely recognized as a common pathogen of nosocomial respiratory
      tract infections.

      There is still a need for observations of clinical experiences to better define the
      risk-benefit profile of ceftolozane-tazobactam. The aim of this study is to report our
      experience with ceftolozane-tazobactam and to evaluate its safety and efficacy in the
      treatment of ICU dependent nosocomial respiratory tract infections due to extensively drug
      resistant Pseudomonas aeruginosa. Different dosing regimes of ceftalozane-tazobactam is
      evaluated and compared to the standard therapy of Colomycin.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 18, 2018</start_date>
  <completion_date type="Anticipated">May 19, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 19, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical cure rate</measure>
    <time_frame>7-14 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Microbiological cure rate</measure>
    <time_frame>7-14 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>LOS</measure>
    <time_frame>28</time_frame>
    <description>Lenght of ICU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ventilation</measure>
    <time_frame>Untill patient is ventilated (expected time frame is 10 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28 day mortality</measure>
    <time_frame>28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug related adverse events rate</measure>
    <time_frame>until ICU discharge (expected average day is 14)</time_frame>
    <description>The number and nature</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">55</enrollment>
  <condition>Ventilator Associated Pneumonia</condition>
  <condition>Antibiotic Resistant Infection</condition>
  <arm_group>
    <arm_group_label>C/T</arm_group_label>
    <description>C/T cases: individuals fulfilling eligibility criteria and treated with ceftolozane-tazobactam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <description>C cases: individuals fulfilling eligibility criteria and treated with colomycine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftolozane/tazobactam</intervention_name>
    <description>Administration</description>
    <arm_group_label>C/T</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to a multideisciplanry academic terciary care ICU, suffering from
        ventilation associated pneumonia, caused by XDR or panresistant Pseudomonas Aeruginosa
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospital-acquired pneumonia caused by extensively drug-resistant Pseudomonas
             aeruginosa

          -  ≥ 72 hours of targeted antibiotic therapy against Pseudomonas aeruginosa with either
             Colomycin or Ceftolozane-Tazobactam

        Exclusion Criteria:

          -  Participation in an interventional trial aiming nosocomial infections

          -  Treatment was not with the intent to cure the infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Semmelweis University</name>
      <address>
        <city>Budapest</city>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>April 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2020</study_first_posted>
  <last_update_submitted>April 15, 2020</last_update_submitted>
  <last_update_submitted_qc>April 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Semmelweis University</investigator_affiliation>
    <investigator_full_name>Zsolt Iványi</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Ceftolozane</mesh_term>
    <mesh_term>Ceftolozane, tazobactam drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

